Abstract
Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.
Current Pharmaceutical Design
Title: Targeted Delivery of Anti-Inflammatory Agents to Tumors
Volume: 15 Issue: 16
Author(s): Maria Coimbra, Sylvia A. Kuijpers, Sebastiaan P. van Seters, Gert Storm and Raymond M. Schiffelers
Affiliation:
Abstract: Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.
Export Options
About this article
Cite this article as:
Coimbra Maria, Kuijpers A. Sylvia, van Seters P. Sebastiaan, Storm Gert and Schiffelers M. Raymond, Targeted Delivery of Anti-Inflammatory Agents to Tumors, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453220
DOI https://dx.doi.org/10.2174/138161209788453220 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Effects of Ghrelin and Growth Hormone Secretagogues
Cardiovascular & Hematological Disorders-Drug Targets Alstrom Syndrome: Genetics and Clinical Overview
Current Genomics Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice
Current Cardiology Reviews Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Drug Metabolism and Pharmacokinetic Diversity of Ranunculaceae Medicinal Compounds
Current Drug Metabolism Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets Anti-Inflammatory and Antioxidant Properties of a New Arylidene-Thiazolidinedione in Macrophages
Current Medicinal Chemistry Tuberculosis Deaths Among Populations with High HIV Prevalence
Current Respiratory Medicine Reviews Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks
Current Drug Metabolism Central Hemodynamics in Risk Assessment Strategies: Additive Value Over and Above Brachial Blood Pressure
Current Pharmaceutical Design Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets The Effects of Glucose-Lowering Therapies on Diabetic Kidney Disease
Current Diabetes Reviews Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry